TD Cowen lowered the firm’s price target on Ultragenyx (RARE) to $75 from $86 and keeps a Buy rating on the shares. The firm said Crysvita Q3 revenues beat, Dojolvi in line, and total revenues were light. FY25 guidance and FY27 profitability reaffirmed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: